Blood Antibody Signatures Emerge Long Before Inflammatory Bowel Disease Diagnosis
A decade before a clinician labels a patient with inflammatory bowel disease, the immune system may already be broadcasting clues in the blood. Researchers presenting data at UEG Week 2026 identified antibody patterns that separated people who later developed Crohn’s disease or ulcerative colitis from healthy controls as far back as 10 years before diagnosis.
The work matters because IBD rarely appears out of nowhere. Long before abdominal pain, diarrhea, rectal bleeding, weight loss, or the need for endoscopy, a quieter biological process seems to be unfolding. In this cohort, those preclinical changes were visible in serum, where the immune system’s targeting behavior had already become measurably different from that of healthy participants.
The study examined 2,000 blood serum samples from 500 people. Among them were 200 who later developed Crohn’s disease, 200 who later developed ulcerative colitis, and 100 healthy individuals matched for age and sex. Samples were available at diagnosis and at roughly two, four, and 10 years beforehand, allowing investigators to trace immune activity backward through time rather than looking only at the moment disease became clinically obvious.
Across the full sample set, the researchers measured antibody reactivity against roughly 357,000 antigens derived from bacteria, viruses, food, and components of the immune system itself. The scale of that profiling is part of what makes the findings clinically interesting. This was not a narrow search for one biomarker; it was a broad survey of humoral immunity, designed to catch patterns that might otherwise remain hidden in routine care.
Narrower Antibody Diversity Marked Future IBD Cases
The clearest signal was a loss of breadth. People who later developed Crohn’s disease or ulcerative colitis had significantly less antibody diversity than healthy participants, suggesting that their immune systems were responding to a narrower range of targets. In practical terms, the antibody repertoire was less varied years before diagnosis, implying an early shift in immune surveillance or immune tolerance.
That pattern appeared well before symptoms, which is clinically important. A preclinical immune signature means the disease process may begin long before patients reach gastroenterology clinics, and before inflammation becomes severe enough to trigger standard diagnostic pathways. The blood already carried a record of that hidden evolution.
Across all samples, the investigators identified 123,980 unique antibodies. Within that massive set, disease-linked patterns separated future IBD cases from healthy controls and emerged by 10 years before diagnosis. For Crohn’s disease and ulcerative colitis, the trajectories were not identical. Each disorder appeared to leave its own immunologic fingerprint.
Crohn’s Disease and Ulcerative Colitis Carried Different Immune Patterns
The Crohn’s disease profile stood out for elevated antibody responses to herpesviruses and bacterial flagellin. Flagellin is the structural protein that helps some bacteria move, and a heightened response to it suggests immune recognition of bacterial motility machinery. In Crohn’s disease, that response was especially pronounced among people who later developed complicated disease or disease affecting the ileum, the terminal portion of the small intestine where Crohn’s often concentrates and where transmural inflammation can become clinically consequential.
At the same time, antibody responses to encapsulated bacteria gradually decreased as diagnosis approached. Encapsulated organisms are protected by outer coatings that help them evade host defenses, so a falling response may reflect a broader remodeling of mucosal immunity rather than a single isolated reaction.
Ulcerative colitis followed a different path. Future ulcerative colitis cases showed rising antibody responses to herpesviruses and autoantigens, alongside declining responses to encapsulated pathogens. Autoantigens are the body’s own molecular structures, and a growing response to them points toward a loss of immune restraint. In a disease centered in the colon and associated with chronic mucosal inflammation, that pattern fits an immune system that is increasingly misdirected even before the first formal diagnosis.
The separation between the two conditions is clinically useful. Crohn’s disease and ulcerative colitis share overlapping symptoms, but they differ in anatomy, complications, and treatment strategy. A blood test that can distinguish them years before diagnosis would do more than flag risk; it could help clinicians anticipate the type of disease a patient is likely to develop.
Machine Learning Detected Future IBD With High Discrimination
To test whether these antibody signatures had predictive value, investigators used machine learning to distinguish future IBD cases from healthy controls. The model performed well. Using blood antibody patterns from up to 10 years before diagnosis, it identified future Crohn’s disease with an area under the curve of 0.90 and future ulcerative colitis with an area under the curve of 0.84.
The model also separated people who would later develop complicated Crohn’s disease from those with less complicated illness, reaching an area under the curve of 0.85 approximately 10 years before diagnosis. That finding is especially relevant to bedside decision-making. In Crohn’s disease, complication risk often drives how aggressively clinicians monitor, image, and treat patients. If a risk signature can be recognized years in advance, it could eventually inform earlier surveillance or earlier use of more intensive therapy.
Lead author Dr. Arno Bourgonje put the biologic implication plainly: complicated Crohn’s disease at diagnosis was associated with a distinct antibody profile years before the first clinical symptoms and was not simply the result of progression after diagnosis. The implication is that severe disease may begin as a distinct biological trajectory rather than a later-stage accident of untreated inflammation.
Screening Potential Remains Experimental, Not Ready for Routine Use
The findings are striking, but they do not yet justify routine screening. The study establishes proof of principle, not a clinical test ready for the outpatient clinic or population-wide screening programs. Independent validation in broader and more diverse cohorts is still needed, and prospective follow-up will matter more than retrospective reconstruction if these signatures are to be used in real-world care.
Several questions still need direct answers. Researchers must determine whether antibody profiling adds meaningful information beyond genetics, clinical risk factors, and other blood-based markers. They also have to show that any assay can be made reproducible, affordable, and practical for clinical laboratories. Most important, future trials will need to show that acting on this information improves outcomes rather than merely predicting them.
For now, the study points to a long preclinical window in inflammatory bowel disease, with the immune system leaving detectable traces years before diagnosis. The path from signal to screening remains long, and the next step is validation in independently followed populations with real clinical endpoints rather than biomarker performance alone.